CNS Pharmaceuticals Reports Decreased Net Losses and Increased Cash Reserves for Q3 2025

CNS Pharmaceuticals, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net loss of approximately $3.2 million for the three months ended September 30, 2025, a significant decrease from the $5.6 million loss reported in the same period in 2024. For the nine-month period, the company recorded a net loss of about $9.9 million, down from $11.7 million in the prior year. The reduction in losses is attributed to decreased operating expenses, particularly in research and development, which fell to $2.2 million in Q3 2025 from $4.2 million in Q3 2024, and to $6.6 million for the nine months ending September 30, 2025, compared to $7.8 million for the same period in 2024.

Total operating expenses for the third quarter of 2025 were approximately $3.3 million, down from $5.6 million in the prior year. The decline in expenses was primarily driven by a reduction in trial costs associated with the Berubicin trial and lower general and administrative expenses, which decreased to $1.1 million from $1.4 million year-over-year. The company’s cash and cash equivalents increased to approximately $9.9 million as of September 30, 2025, compared to $6.5 million at the end of 2024, reflecting a positive cash flow from financing activities, which totaled about $14.2 million for the nine months ended September 30, 2025.

CNS Pharmaceuticals has been actively pursuing strategic developments, including a reverse stock split executed on July 22, 2025, at a ratio of 1-for-12, aimed at improving its stock price and compliance with Nasdaq listing requirements. The company has also entered into a Sales Agreement with A.G.P./Alliance Global Partners, allowing it to sell shares of common stock, which has generated approximately $9 million in net proceeds during the nine months ended September 30, 2025. Additionally, the company has been focusing on the development of its drug candidates, TPI 287 and Berubicin, which are aimed at treating glioblastoma and other central nervous system tumors.

Operationally, CNS Pharmaceuticals has made progress in its clinical trials, particularly with Berubicin, which has shown potential value despite not achieving statistically significant differences in overall survival compared to the current standard of care, Lomustine. The company is currently evaluating potential paths forward for Berubicin in consultation with the FDA. As of September 30, 2025, CNS Pharmaceuticals had a total of 574,580 shares of common stock issued and outstanding, reflecting its ongoing efforts to raise capital and support its clinical development programs.

Looking ahead, CNS Pharmaceuticals anticipates that its current cash reserves will be sufficient to fund operations into the second half of 2026, assuming a core operational expense run rate of approximately $5.5 million per year. However, the company acknowledges the need for significant additional financing to support the costs associated with bringing TPI 287 to regulatory approval, which is estimated to range between $12 million to $15 million. The company has not secured commitments for this additional funding and may need to explore further equity or debt financing options to continue its operations and clinical development efforts.